Novartis works on pan-coronavirus pill, eyes 2022 human testing

Unlike some of its Big Pharma peers, Novartis has not been at the forefront of creating new vaccines and treatments against COVID: Now, however, it’s taking its massive R&D budget and targeting not just the current pandemic, but all coronaviruses.